Publications by authors named "P Thill"
Article Synopsis
- Prosthetic joint infections (PJIs) caused by Candida species are serious complications following joint replacement surgeries, with a study reviewing 269 cases between 2010 and 2021 to assess treatment outcomes.
- The majority of infections occurred in older patients (average age 73), primarily in hips and knees, and most cases involved additional bacterial infections; roughly 58% achieved a cure at the two-year follow-up.
- Treatment effectiveness varied significantly depending on the surgical method used, with poorer outcomes linked to the debridement, antibiotics, and implant retention (DAIR) approach and patients older than 70, while infections from Candida parapsilosis tended to have better outcomes.
Background: In 2012, Luxembourg introduced a Referring Doctor (RD) policy, whereby patients voluntarily register with a primary care practitioner, who coordinates patients' health care and ensures optimal follow-up. We contribute to the limited evidence base on patient registration by evaluating the effects of the RD policy.
Methods: We used data on 16,775 people with type 2 diabetes on oral medication (PWT2D), enrolled with the Luxembourg National Fund from 2010 to 2018.
Objectives: We aimed to describe the efficacy and safety of dalbavancin in treatment of patients with diabetes-related foot osteomyelitis with bone culture confirmation.
Patients And Methods: Between January 2019 and December 2021, all consecutive patients receiving at least one 1500 mg dose of dalbavancin for diabetes-related foot osteomyelitis were included in a retrospective study. Remission was defined as absence of relapsing infection or need for surgery at the initial or a contiguous site during 6-month follow-up from the last dose of dalbavancin.
Introduction: Since 2017, pre-exposure prophylaxis (PrEP) has been one of the tools in combination HIV prevention strategies. The objective of our questionnaire was to analyze the knowledge and the position of general practitioners in Hauts-de-France on PrEP.
Method: This quantitative, observational, cross-sectional study was conducted in 2020 using an anonymous questionnaire sent by post to a sample of 3007 GPs.
Pharmacovigilance for COVID-19 vaccines: A 1-year experience in France.
Infect Dis Now
November 2022
As of February 2022, more than 130 million Covid vaccine doses had been distributed in France. During the first year of relevant vaccination, 128,766 adverse events (AE) were reported and analysed, as compared to an average of 40,000 per year for all drugs combined in the pre-pandemic years. A weekly monitoring committee was set up.
View Article and Find Full Text PDF